British Columbia Investment Management Decreased Alexion Pharmaceuticals (ALXN) Holding By $9.71 Million; First Solar Has 1.16 Sentiment

February 18, 2018 - By Vivian Currie

First Solar, Inc. provides solar energy solutions in the United States and internationally. The company has market cap of $6.88 billion. It operates through two divisions, Components and Systems. It currently has negative earnings. The Components segment designs, makes, and sells cadmium telluride solar modules that convert sunlight into electricity.

British Columbia Investment Management Corp decreased Alexion Pharmaceuticals Inc (ALXN) stake by 42.4% reported in 2017Q3 SEC filing. British Columbia Investment Management Corp sold 69,384 shares as Alexion Pharmaceuticals Inc (ALXN)’s stock declined 11.63%. The British Columbia Investment Management Corp holds 94,257 shares with $13.22M value, down from 163,641 last quarter. Alexion Pharmaceuticals Inc now has $26.71 billion valuation. The stock decreased 1.83% or $2.24 during the last trading session, reaching $120.47. About 3.90M shares traded or 81.87% up from the average. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since February 18, 2017 and is downtrending. It has underperformed by 34.82% the S&P500.

Analysts await First Solar, Inc. (NASDAQ:FSLR) to report earnings on February, 20. They expect $-0.33 EPS, down 126.61% or $1.57 from last year’s $1.24 per share. After $1.95 actual EPS reported by First Solar, Inc. for the previous quarter, Wall Street now forecasts -116.92% negative EPS growth.

Since January 1, 0001, it had 0 insider purchases, and 2 insider sales for $1.83 million activity.

Ecofin Ltd holds 10.38% of its portfolio in First Solar, Inc. for 943,979 shares. Domini Impact Investments Llc owns 6,935 shares or 7.23% of their US portfolio. Moreover, Rit Capital Partners Plc has 7.2% invested in the company for 74,200 shares. The Vermont-based Prentiss Smith & Co Inc has invested 1.87% in the stock. Agf Investments America Inc., a Ontario – Canada-based fund reported 60,371 shares.

The stock increased 0.05% or $0.03 during the last trading session, reaching $65.85. About 1.19 million shares traded. First Solar, Inc. (FSLR) has declined 22.83% since February 18, 2017 and is downtrending. It has underperformed by 39.53% the S&P500.

Ratings analysis reveals 11% of First Solar’s analysts are positive. Out of 9 Wall Street analysts rating First Solar, 1 give it “Buy”, 4 “Sell” rating, while 4 recommend “Hold”. The lowest target is $25.0 while the high is $50.0. The stock’s average target of $37 is -43.81% below today’s ($65.85) share price. FSLR was included in 9 notes of analysts from September 8, 2016. Piper Jaffray initiated First Solar, Inc. (NASDAQ:FSLR) rating on Monday, October 10. Piper Jaffray has “Neutral” rating and $43.0 target. UBS downgraded it to “Sell” rating and $25.0 target in Friday, November 18 report. Macquarie Research downgraded First Solar, Inc. (NASDAQ:FSLR) on Wednesday, November 23 to “Neutral” rating. The firm has “Mkt Underperform” rating by Avondale given on Thursday, November 17. The firm has “Underperform” rating given on Wednesday, February 22 by Credit Suisse. Williams Capital Group initiated the shares of FSLR in report on Friday, September 30 with “Buy” rating. The stock of First Solar, Inc. (NASDAQ:FSLR) has “Mkt Underperform” rating given on Thursday, September 8 by JMP Securities. The stock has “Neutral” rating by Goldman Sachs on Friday, October 7. The firm has “Neutral” rating by Mizuho given on Thursday, November 17.

Among 29 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 24 have Buy rating, 0 Sell and 5 Hold. Therefore 83% are positive. Alexion Pharmaceuticals Inc. had 100 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Wednesday, January 20 by Credit Suisse. The firm has “Outperform” rating given on Wednesday, July 13 by RBC Capital Markets. As per Thursday, May 25, the company rating was upgraded by Morgan Stanley. On Thursday, January 7 the stock rating was initiated by SunTrust with “Buy”. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Buy” rating given on Monday, September 25 by Leerink Swann. The stock has “Buy” rating by Oppenheimer on Tuesday, August 15. The company was maintained on Tuesday, October 24 by Leerink Swann. Morgan Stanley maintained the stock with “Overweight” rating in Tuesday, June 7 report. Deutsche Bank maintained the shares of ALXN in report on Friday, February 9 with “Buy” rating. The firm has “Equal-Weight” rating by Morgan Stanley given on Tuesday, December 13.

British Columbia Investment Management Corp increased Mercadolibre Inc (NASDAQ:MELI) stake by 5,412 shares to 16,680 valued at $4.32M in 2017Q3. It also upped Valero Energy Corp New (NYSE:VLO) stake by 84,254 shares and now owns 339,163 shares. Targa Res Corp (NYSE:TRGP) was raised too.

Since August 28, 2017, it had 0 insider purchases, and 14 selling transactions for $6.68 million activity. The insider Veneman Ann M sold 835 shares worth $121,751. $147,865 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was sold by Moriarty John B on Monday, February 5. $1.56 million worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was sold by O’Neill Julie. Another trade for 655 shares valued at $76,805 was made by Wagner Heidi L on Monday, February 5. Another trade for 2,553 shares valued at $310,521 was made by HANTSON LUDWIG on Tuesday, January 2. Another trade for 1,651 shares valued at $192,028 was sold by Goff Brian. 6,079 shares were sold by Clancy Paul J, worth $707,048.

Investors sentiment decreased to 1.17 in 2017 Q3. Its down 0.20, from 1.37 in 2017Q2. It dropped, as 36 investors sold ALXN shares while 174 reduced holdings. 78 funds opened positions while 167 raised stakes. 206.89 million shares or 0.54% less from 208.01 million shares in 2017Q2 were reported. Gateway Invest Advisers Lc has 140,338 shares for 0.17% of their portfolio. Ameriprise Incorporated has 6.39 million shares. Louisiana State Employees Retirement has invested 0.09% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Zurcher Kantonalbank (Zurich Cantonalbank) holds 0.06% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 48,360 shares. Moreover, Huntington Savings Bank has 0% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Spark Investment Mgmt Limited Liability Corporation reported 0.36% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Synovus Corp holds 0.01% or 2,047 shares in its portfolio. Thornburg Management holds 101,600 shares or 0.1% of its portfolio. D E Shaw Co reported 115,759 shares. Rhenman And Prtn Asset Mgmt holds 2.96% or 165,000 shares. Vident Inv Advisory Ltd Co stated it has 8,065 shares. Van Eck Associate Corp holds 0.16% or 224,419 shares in its portfolio. Hills Savings Bank holds 3,935 shares or 0.17% of its portfolio. Wells Fargo And Communication Mn invested in 1.56M shares. California State Teachers Retirement System accumulated 367,615 shares or 0.11% of the stock.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: